* | Estimated solely for purposes of calculating the amount of the filing fee only. The transaction valuation was calculated by adding (a) the product of (i) $48.00, the purchase price per share (the “Offer Price”) of DICE Therapeutics, Inc. (“DICE”) common stock, par value $0.0001 per share (each such share, a “Share”), net to the stockholder in cash, without interest and less any applicable tax withholding, and (ii) 47,790,092 Shares issued and outstanding, (b) the product of (i) 4,828,189 Shares issuable pursuant to outstanding options with an exercise price less than the Offer Price and (ii) $25.83, the difference between the Offer Price and $22.17, the weighted average exercise price for such options, (c) the product of (i) 244,150 Shares issuable pursuant to outstanding restricted stock units and (ii) the Offer Price, and (d) the product of (i) 42,349 Shares issuable pursuant to outstanding warrants to purchase Shares and (ii) $33.57, the difference between the Offer Price and $14.43, the exercise price for such warrants. The calculation of the filing fee is based on information provided by DICE as of June 26, 2023. |